Stock News

Welcome to the Kosmos Energy Tender Offers! What’s the Buzz All About? It’s a big day for Kosmos Energy Ltd. as they announce the launch of their Tender Offers to purchase outstanding senior notes. The Offeror is offering to purchase up to $400,000,000 of their 7.125% Senior Notes due 2026 and up to $100,000,000 of…

Welcome to the Future of Cancer Treatment Hemogenyx Pharmaceuticals: Leading the Way September 9, 2024 London, United Kingdom – Hemogenyx Pharmaceuticals plc (LSE:HEMO), a pioneer in the field of biopharmaceuticals, has achieved a significant milestone in the development of a groundbreaking clinical-grade assay. This assay, designed to assess FLT3 protein expression in acute myeloid leukemia…

Get ready for some financial jargon! What just went down in Aura Minerals Inc. So, in case you missed it, Aura Minerals Inc. just had a major development with its subsidiary, Aura Almas Mineração S.A. The company held an Extraordinary Shareholders’ General Meeting and got the green light for the issuance of some serious debentures….

Exciting News for C4 Therapeutics, Inc.: Abstract Released Highlighting Favorable Safety Profile and Early Anti-Tumor Activity Investor Webcast Scheduled for September 13, 2024 WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced today that the abstract sharing clinical data from its Phase 1 clinical trial of CFT1946 was released…

Levi & Korsinsky Investigation of Liquidia Corporation Concerns Over Violations of Federal Securities Laws In a recent development, Levi & Korsinsky has initiated an investigation into Liquidia Corporation (NASDAQ:LQDA) for potential breaches of federal securities laws. This investigation comes in light of a significant drop in Liquidia’s stock price, which plummeted by 35% on August…

Investigation of Dyne Therapeutics, Inc. by Bronstein, Gewirtz & Grossman, LLC Overview New York–(BUSINESS WIRE)—- Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC is currently conducting an investigation on behalf of investors who have purchased Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN). Investors who have acquired Dyne securities are encouraged to gather further details and…

Welcome to the MARIPOSA study: A Comedy of Errors in Lung Cancer Treatments The Plot Thickens: RYBREVANT® Plus LAZCLUZE™ Regimen vs Osimertinib Monotherapy Picture this: a group of scientists and researchers at Johnson & Johnson gather around a table, scratching their heads over how to best treat advanced non-small cell lung cancer. They throw around…

I recently made a bold decision to upgrade Alphabet Inc. (GOOG) from a “Hold” to a “Buy” rating, and let me tell you why. Market Pessimism and Valuation First off, let’s address the elephant in the room – the market pessimism surrounding Alphabet Inc. Many investors have been wary of the low return on investment…